Measuring relatively new biomarkers such as Kidney Injury Marker-1 (KIM-1) and Neutrophil Gelatinase-Associated Lipocalin (NGAL) may improve personalized medicine by diagnosing patients correctly and quickly (earlier than existing methods allow) so that treatment can be administered based on the particular needs of the patient [146–148]. Here, LCN2 is linked to kidney injury.